What Does Conformis, Inc.'s (NASDAQ:CFMS) Balance Sheet Tell Us About It?

Conformis, Inc. (NASDAQ:CFMS) is a small-cap stock with a market capitalization of US$158m. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. Why is it important? Since CFMS is loss-making right now, it’s essential to assess the current state of its operations and pathway to profitability. Let's work through some financial health checks you may wish to consider if you're interested in this stock. However, this is just a partial view of the stock, and I recommend you dig deeper yourself into CFMS here.

Advertisement

CFMS’s Debt (And Cash Flows)

Over the past year, CFMS has reduced its debt from US$30m to US$15m , which includes long-term debt. With this reduction in debt, CFMS's cash and short-term investments stands at US$24m , ready to be used for running the business. We note it produced negative cash flow over the last twelve months. As the purpose of this article is a high-level overview, I won’t be looking at this today, but you can assess some of CFMS’s operating efficiency ratios such as ROA here.

Can CFMS meet its short-term obligations with the cash in hand?

At the current liabilities level of US$11m, the company has maintained a safe level of current assets to meet its obligations, with the current ratio last standing at 4.22x. The current ratio is calculated by dividing current assets by current liabilities. Having said that, a ratio above 3x may be considered excessive by some investors.

NasdaqGS:CFMS Historical Debt, April 8th 2019
NasdaqGS:CFMS Historical Debt, April 8th 2019

Is CFMS’s debt level acceptable?

With a debt-to-equity ratio of 41%, CFMS can be considered as an above-average leveraged company. This is somewhat unusual for small-caps companies, since lenders are often hesitant to provide attractive interest rates to less-established businesses. Though, since CFMS is currently unprofitable, sustainability of its current state of operations becomes a concern. Running high debt, while not yet making money, can be risky in unexpected downturns as liquidity may dry up, making it hard to operate.

Next Steps:

CFMS’s high cash coverage means that, although its debt levels are high, the company is able to utilise its borrowings efficiently in order to generate cash flow. This may mean this is an optimal capital structure for the business, given that it is also meeting its short-term commitment. I admit this is a fairly basic analysis for CFMS's financial health. Other important fundamentals need to be considered alongside. I recommend you continue to research Conformis to get a more holistic view of the small-cap by looking at:

  1. Future Outlook: What are well-informed industry analysts predicting for CFMS’s future growth? Take a look at our free research report of analyst consensus for CFMS’s outlook.
  2. Historical Performance: What has CFMS's returns been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.

About NasdaqCM:CFMS

Conformis

Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation.

Fair value with mediocre balance sheet.

Advertisement

Weekly Picks

LO
Lou_Basenese
CUE logo
Lou_Basenese on Cue Biopharma ·

Cue Biopharma (NASDAQ: CUE): The Scientist Behind Xolair Just Gave Cue a Next-Generation Shot at the Same Multi-Billion-Dollar Market

Fair Value:US$7056.5% undervalued
25 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative
HA
HarishPK
ADBE logo
HarishPK on Adobe ·

Adobe: A Probabilistic Case for Undervaluation

Fair Value:US$317.225.0% undervalued
28 users have followed this narrative
7 users have commented on this narrative
9 users have liked this narrative
NI
niteco
AVGO logo
niteco on Broadcom ·

A Capital Allocation Favorite with Structural Importance

Fair Value:US$651.0539.8% undervalued
24 users have followed this narrative
0 users have commented on this narrative
3 users have liked this narrative
TO
Tokyo
OKTA logo
Tokyo on Okta ·

Good foundation, but now it's all about the next steps

Fair Value:US$15120.6% undervalued
83 users have followed this narrative
7 users have commented on this narrative
11 users have liked this narrative

Updated Narratives

TE
ZENITHBANK logo
Terence on Zenith Bank ·

Zenith Bank's Revenue To Surge by 18% in the Coming Years

Fair Value:₦93.5936.4% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
MA
MarkoVT
5032 logo
MarkoVT on ANYCOLOR ·

Near zero debt, Japan centric focus provides future growth

Fair Value:JP¥4.05k29.1% undervalued
6 users have followed this narrative
0 users have commented on this narrative
1 users have liked this narrative
RO
RockeTeller
AUMB logo
RockeTeller on 1911 Gold ·

1911 Gold, This Junior Gold Stock Has a 105% IRR and a 2027 Production Target

Fair Value:CA$12.7295.1% undervalued
87 users have followed this narrative
12 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

MA
martinarauz
NU logo
martinarauz on Nu Holdings ·

Investment Analysis (May 2026)

Fair Value:US$22.7447.8% undervalued
58 users have followed this narrative
0 users have commented on this narrative
15 users have liked this narrative
CL
Clive_Thompson
TTWO logo
Clive_Thompson on Take-Two Interactive Software ·

Take-Two Interactive: The Calm Before the Storm NASDAQ: TTWO Last Price: $242.41 Date: May 15, 2026

Fair Value:US$276.9723.4% undervalued
57 users have followed this narrative
0 users have commented on this narrative
14 users have liked this narrative
NI
niteco
HON logo
niteco on Honeywell International ·

Honeywell - The Demand-Side of the AI Infrastructure

Fair Value:US$320.1932.6% undervalued
48 users have followed this narrative
0 users have commented on this narrative
19 users have liked this narrative